C4 Therapeutics, Inc. (CCCC): Total Assets
$359.07M
As of 2025-12-31
$359.40M
As of 2026-06-30
-5.9%
3-year compound annual growth
-2.1%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $359.07M | +2.7% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $349.60M | -7.1% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $376.45M | -12.6% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $430.84M | -15.0% | 2024-02-22, Balance as of period end |
| 2021-12-31 | $506.76M | +26.6% | 2023-02-23, Balance as of period end |
| 2020-12-31 | $400.14M | +238.4% | 2022-02-24, Balance as of period end |
| 2019-12-31 | $118.26M | n/a | 2021-03-11, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | $359.07M | +2.7% |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $290.46M | +98.3% |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | $154.42M | +13.2% |
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | $1.74B | +78.2% |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | $59.74M | -41.2% |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | $252.28M | -35.8% |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $186.53M | -45.4% |
| Scilex Holding Co (SCLX) | 2025-12-31 | $364.98M | +292.7% |
| Fennec Pharmaceuticals Inc. (FENC) | 2025-12-31 | $70.55M | +57.0% |
Compare CCCC, XFOR, DTIL, KYMR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗